Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100. For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price. Analyst Courtney Breen feels Wall Street still isn't factoring in how massive the company’s next wave of GLP-1 catalysts could be. She feels Lilly’s incredible leap into the trillion-dollar club, as reported by Reuters, ...